Developer docs
API playgroundTry for free, no card

Search company profiles

C&R Research

Full company profile

uuid000zp7t

Namestring
C&R Research
Legal namestring
C&R Research Co., Ltd.
Websiteurl
cnrres.com
Company typeenum
Private
Founded yearint
1997
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersYeoksamdong, South Korea
HQ citystring
Yeoksamdong
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial services, contract research organization, drug development consulting, regulatory affairs services, biostatistics and data management
Industry6 codes
1Clinical CROs (Phase I–IV)
CodeHLAGAAAAPrimaryYes
2Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
CodeHLAGAAALPrimaryNo
3Clinical Data Management, Biostatistics & Statistical Programming CROs
CodeHLAGAAAFPrimaryNo
4Real-World Evidence (RWE), HEOR & Epidemiology CROs
CodeHLAGAAAKPrimaryNo
5Pharmacovigilance, Risk Management & Medical Affairs CROs
CodeHLAGAAAHPrimaryNo
6Medical Writing & Regulatory Submission Support CROs
CodeHLAGAAAGPrimaryNo
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Organization (CRO) Services
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1CRO Contract Research Services
TypeProfessional Services
Description

Full-service Contract Research Organization providing end-to-end clinical trial services including Phase 1-4 clinical trials, NIS/OS, PMS, and medical device studies. Revenue generated through project-based contracts with pharmaceutical, biotech, and medical device companies.

cnrres.com
2Specialized Clinical Consulting
TypeProfessional Services
Description

Medical advisory, regulatory consulting, pharmacometric analysis, and training services through C&R Academy, which is an MFDS-designated clinical trial education institution.

cnrres.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1imtrial
Description

Clinical process automation platform developed by C&R Research, providing MDR (Metadata Repository) and TDLM (Trial Data Lifecycle Management) services for clinical trial data management, eCRF auto-generation, and SDTM Package automation.

cnrres.com
+1 more record
Core offering1 text field

C&R Research is Korea's first independent Contract Research Organization (CRO), founded in 1997, providing end-to-end clinical trial services for pharmaceutical, biotechnology, and medical device companies. Services span Phase 1-4 clinical trials, real-world studies, post-marketing surveillance, regulatory affairs, data management, biostatistics, pharmacovigilance, quality management, and medical device trials. The company has conducted 1,800+ trials with 500+ clinical experts and operates its proprietary imtrial clinical process automation platform.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

C&R Research (씨엔알리서치) is Korea's first independent CRO, established in 1997 with over 500 employees. The company provides end-to-end clinical trial services across the full drug development lifecycle from first-in-human through NDA approval. Its core product is Full Service CRO offerings including Medical Advisory & Consulting, Early-Phase Clinical Development, Trial Management (Phase 1-3 and Real-World), Regulatory Affairs, Data Management, Biostatistics, Pharmacovigilance, and Quality Management. Key proprietary platforms include imtrial, a clinical process automation platform providing MDR and TDLM services with standard API access, and C&R Academy, a MFDS-designated clinical education institution. Subsidiaries include Trial Informatics (US-based EDC platform), TI Image (clinical imaging CRO), Mediplexus (RWD/RWE data specialist), and C&R Healthcare Global (ASEAN regional HQ). Services span oncology, rare diseases, cardiovascular, endocrinology, dermatology, ophthalmology, CNS, and cover biotechnology (biosimilars, CAR-T, cell/gene therapy, ADC), pharmaceuticals (novel drugs, improved drugs, generics), and medical devices sectors. The company holds KoNECT Innovative CRO certification (2023) and operates globally with offices in the US, Singapore, Thailand, and Indonesia.

Product and service3 records
1Full Service CRO
CategoryContract Research Organization Services
Description

End-to-end clinical trial services from researcher selection through NDA approval, covering clinical trial planning, IND applications, trial operations, data management, statistical analysis, and result reporting for pharmaceutical, biotech, and medical device companies.

2imtrial Platform
CategoryClinical Trial Technology Platform
Description

Clinical process automation platform providing MDR (Metadata Repository) and TDLM (Trial Data Lifecycle Management) services for standardized data storage, eCRF auto-generation, and SDTM Package automation. Includes standard API access for integration with clinical research platforms and CROs.

3C&R Academy
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-04
Description

C&R Research contracted to conduct US pivotal clinical trial for AIMneXt's digital therapeutic Somzz (Korea's first approved DTx for insomnia). C&R's medical device team and US subsidiary Trial Informatics collaborating to support AIMneXt's FDA approval process.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-18
Description

Strategic agreement with Vietnam CRO company VietStar Biomedical Research to build multi-country clinical operational system in Southeast Asia and strengthen local clinical execution capabilities.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-18
Description

Strategic agreement with Vietnam CRO company Smart Research to build multi-country clinical operational system in Southeast Asia and strengthen local clinical execution capabilities.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-07
Description

Strategic partnership to develop AI-based clinical trial operations system. C&R Research deploying Taimei Technology's digital infrastructure and AI Agents including EDC + iDM Agent combination across multiple clinical trials. Focus on automating trial design and operational workflows, including AI-driven eCRF generation and automated test case creation. C&R secured 1-year exclusive rights for Taimei AI Agent in Korea.

5KoNECT (Korea National Enterprise for Clinical Trials)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-20
Description

Business agreement with KoNECT for global clinical trial expansion cooperation. C&R supporting domestic companies' overseas advancement based on global clinical experience and network, while strengthening domestic clinical trial ecosystem competitiveness.

cnrres.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

MOU signed in 2024 with Thailand subsidiary to strengthen Korea-Thailand clinical cooperation and expand regional frameworks supporting Korean pharmaceutical companies' entry into ASEAN markets.

Strategic tierCoreTypeTechnology or Integration
Description

US subsidiary providing proprietary EDC platform for clinical trial data management. Collaborates with C&R medical device team for US clinical trial operations and FDA approval support.

8C&R Healthcare Global (씨엔알헬스케어글로벌)
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

ASEAN clinical overseas subsidiary handling regional clinical operations and business development across Southeast Asia markets.

cnrres.com
9C&R SMO (씨엔알에스엠오)
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Clinical trial site management organization supporting trial execution and site coordination.

cnrres.com
10ABC Bioscience
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Full-cycle drug development consulting company integrated into C&R network for comprehensive service offering.

cnrres.com
Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global CRO providing full-service Phase 1-4 trial management, bioanalytical, and consulting services. Competes for the same Korean and Asian pharma outsourcing contracts as C&R, particularly in multi-region trials.

TypeDirect peer
Description

Mid-sized US-headquartered full-service CRO focused on small-to-mid biotech and pharma sponsors. Comparable in scale and operating model to C&R's full-service offering, though focused primarily on Western markets.

TypeBroad incumbent
Description

Large global CRO spun out from LabCorp offering clinical trial management, central laboratory, and consulting services. Targets similar Korean and Asian pharma clients seeking FDA-compliant clinical development.

TypeBroad incumbent
Description

Global CRO with deep regulatory expertise and FDA submission track record. Direct competitor for Korean pharma seeking US FDA pathway support, an area where C&R is building capability via its Boston subsidiary.

TypeBroad incumbent
Description

World's largest CRO with comprehensive clinical, technology, and consulting services across all phases. Direct competitor for Korean pharma seeking global clinical trials; C&R's VP previously served as IQVIA Korea country manager, illustrating talent flow between the two.

TypeDirect peer
Description

China's largest CRO offering full-service clinical trial management, biostatistics, and regulatory services. Regional peer in Asian CRO market with comparable service breadth and growing international footprint.

TypeBroad incumbent
Description

Global CRO with strong preclinical-to-clinical continuum, particularly in oncology and rare disease. Competes for the same Korean biotech and pharma clients requiring integrated early-stage development.

TypeDirect peer
Description

Korea-headquartered CRO providing clinical trial management and biostatistics services. Most direct domestic competitor to C&R Research in Korean pharma CRO market, with overlapping client base and service offerings.

TypeBroad incumbent
Description

China-headquartered global CRO/CDMO providing comprehensive drug development services including clinical trials. Asian regional competitor with overlapping therapeutic area expertise and global ambitions.

TypeDirect peer
Description

Asia-Pacific-focused CRO providing full-service clinical trial services across the region, particularly Australia and Southeast Asia. Closest direct competitor for Asian multi-country trials and overlapping with C&R's ASEAN expansion strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

C&R Research

Contract Research Organization (CRO) Servicescnrres.com

C&R Research firmographics

Firmographics
Name
C&R Research
Legal name
C&R Research Co., Ltd.
Website
https://cnrres.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

C&R Research industry classification

Industry
Product category
Contract Research Organization (CRO) Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry
Clinical CROs (Phase I–IV) (HLAGAAAA)
akta.pro secondary industries
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Real-World Evidence (RWE), HEOR & Epidemiology CROs (HLAGAAAK), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG)

Keywords

  • Clinical trial services
  • Contract research organization
  • Drug development consulting
  • Regulatory affairs services
  • Biostatistics and data management

Where C&R Research is headquartered

Location

Headquarters

HQ city
Yeoksamdong
HQ country
South Korea
HQ region
Asia

Offices6 records

Markets served

C&R Research business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. CRO Contract Research Services: Full-service Contract Research Organization providing end-to-end clinical trial services including Phase 1-4 clinical trials, NIS/OS, PMS, and medical device studies. Revenue generated through project-based contracts with pharmaceutical, biotech, and medical device companies.
  2. Specialized Clinical Consulting: Medical advisory, regulatory consulting, pharmacometric analysis, and training services through C&R Academy, which is an MFDS-designated clinical trial education institution.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels4 records

C&R Research product offering

Product offering

Core offering

C&R Research is Korea's first independent Contract Research Organization (CRO), founded in 1997, providing end-to-end clinical trial services for pharmaceutical, biotechnology, and medical device companies. Services span Phase 1-4 clinical trials, real-world studies, post-marketing surveillance, regulatory affairs, data management, biostatistics, pharmacovigilance, quality management, and medical device trials. The company has conducted 1,800+ trials with 500+ clinical experts and operates its proprietary imtrial clinical process automation platform.

Product overview

C&R Research (씨엔알리서치) is Korea's first independent CRO, established in 1997 with over 500 employees. The company provides end-to-end clinical trial services across the full drug development lifecycle from first-in-human through NDA approval. Its core product is Full Service CRO offerings including Medical Advisory & Consulting, Early-Phase Clinical Development, Trial Management (Phase 1-3 and Real-World), Regulatory Affairs, Data Management, Biostatistics, Pharmacovigilance, and Quality Management. Key proprietary platforms include imtrial, a clinical process automation platform providing MDR and TDLM services with standard API access, and C&R Academy, a MFDS-designated clinical education institution. Subsidiaries include Trial Informatics (US-based EDC platform), TI Image (clinical imaging CRO), Mediplexus (RWD/RWE data specialist), and C&R Healthcare Global (ASEAN regional HQ). Services span oncology, rare diseases, cardiovascular, endocrinology, dermatology, ophthalmology, CNS, and cover biotechnology (biosimilars, CAR-T, cell/gene therapy, ADC), pharmaceuticals (novel drugs, improved drugs, generics), and medical devices sectors. The company holds KoNECT Innovative CRO certification (2023) and operates globally with offices in the US, Singapore, Thailand, and Indonesia.

Differentiator

Problem solved

Functional benefit

Brands

  • imtrial: Clinical process automation platform developed by C&R Research, providing MDR (Metadata Repository) and TDLM (Trial Data Lifecycle Management) services for clinical trial data management, eCRF auto-generation, and SDTM Package automation.
  • C&R Academy

Products and services

  • Full Service CRO End-to-end clinical trial services from researcher selection through NDA approval, covering clinical trial planning, IND applications, trial operations, data management, statistical analysis, and result reporting for pharmaceutical, biotech, and medical device companies.
  • imtrial Platform Clinical process automation platform providing MDR (Metadata Repository) and TDLM (Trial Data Lifecycle Management) services for standardized data storage, eCRF auto-generation, and SDTM Package automation. Includes standard API access for integration with clinical research platforms and CROs.
  • C&R Academy

Companies that use C&R Research

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

C&R Research technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

C&R Research partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • AIMneXtcoreStrategic or Co-development Partner · 4 June 2026C&R Research contracted to conduct US pivotal clinical trial for AIMneXt's digital therapeutic Somzz (Korea's first approved DTx for insomnia). C&R's medical device team and US subsidiary Trial Informatics collaborating to support AIMneXt's FDA approval process.
  • VietStar Biomedical ResearchminorStrategic or Co-development Partner · 18 May 2026Strategic agreement with Vietnam CRO company VietStar Biomedical Research to build multi-country clinical operational system in Southeast Asia and strengthen local clinical execution capabilities.
  • Smart ResearchminorStrategic or Co-development Partner · 18 May 2026Strategic agreement with Vietnam CRO company Smart Research to build multi-country clinical operational system in Southeast Asia and strengthen local clinical execution capabilities.
  • Taimei TechnologycoreTechnology or Integration · 7 May 2026Strategic partnership to develop AI-based clinical trial operations system. C&R Research deploying Taimei Technology's digital infrastructure and AI Agents including EDC + iDM Agent combination across multiple clinical trials. Focus on automating trial design and operational workflows, including AI-driven eCRF generation and automated test case creation. C&R secured 1-year exclusive rights for Taimei AI Agent in Korea.
  • KoNECT (Korea National Enterprise for Clinical Trials)coreStrategic or Co-development Partner · 20 March 2026Business agreement with KoNECT for global clinical trial expansion cooperation. C&R supporting domestic companies' overseas advancement based on global clinical experience and network, while strengthening domestic clinical trial ecosystem competitiveness.
  • KIMCo (Korea Innovative Medicines Consortium)minorStrategic or Co-development Partner · 1 January 2024MOU signed in 2024 with Thailand subsidiary to strengthen Korea-Thailand clinical cooperation and expand regional frameworks supporting Korean pharmaceutical companies' entry into ASEAN markets.
  • Trial Informatics (트라이얼인포매틱스)coreTechnology or IntegrationUS subsidiary providing proprietary EDC platform for clinical trial data management. Collaborates with C&R medical device team for US clinical trial operations and FDA approval support.
  • C&R Healthcare Global (씨엔알헬스케어글로벌)coreChannel Partner/ Reseller/ DistributorASEAN clinical overseas subsidiary handling regional clinical operations and business development across Southeast Asia markets.
  • C&R SMO (씨엔알에스엠오)minorImplementation/ SI/ Consulting PartnerClinical trial site management organization supporting trial execution and site coordination.
  • ABC BioscienceminorStrategic or Co-development PartnerFull-cycle drug development consulting company integrated into C&R network for comprehensive service offering.

Scale indicators9 records

Recent moves12 records

Expansion highlights7 records

C&R Research competitors and assessment

Company assessment

Broad incumbents

  • ICON plc: Global CRO providing full-service Phase 1-4 trial management, bioanalytical, and consulting services. Competes for the same Korean and Asian pharma outsourcing contracts as C&R, particularly in multi-region trials.
  • Fortrea (formerly LabCorp Drug Development / Covance): Large global CRO spun out from LabCorp offering clinical trial management, central laboratory, and consulting services. Targets similar Korean and Asian pharma clients seeking FDA-compliant clinical development.
  • Parexel: Global CRO with deep regulatory expertise and FDA submission track record. Direct competitor for Korean pharma seeking US FDA pathway support, an area where C&R is building capability via its Boston subsidiary.
  • IQVIA: World's largest CRO with comprehensive clinical, technology, and consulting services across all phases. Direct competitor for Korean pharma seeking global clinical trials; C&R's VP previously served as IQVIA Korea country manager, illustrating talent flow between the two.
  • Charles River Laboratories: Global CRO with strong preclinical-to-clinical continuum, particularly in oncology and rare disease. Competes for the same Korean biotech and pharma clients requiring integrated early-stage development.
  • WuXi AppTec: China-headquartered global CRO/CDMO providing comprehensive drug development services including clinical trials. Asian regional competitor with overlapping therapeutic area expertise and global ambitions.

Direct peers

  • Medpace: Mid-sized US-headquartered full-service CRO focused on small-to-mid biotech and pharma sponsors. Comparable in scale and operating model to C&R's full-service offering, though focused primarily on Western markets.
  • Tigermed: China's largest CRO offering full-service clinical trial management, biostatistics, and regulatory services. Regional peer in Asian CRO market with comparable service breadth and growing international footprint.
  • LSK Global Pharma Services: Korea-headquartered CRO providing clinical trial management and biostatistics services. Most direct domestic competitor to C&R Research in Korean pharma CRO market, with overlapping client base and service offerings.
  • Novotech: Asia-Pacific-focused CRO providing full-service clinical trial services across the region, particularly Australia and Southeast Asia. Closest direct competitor for Asian multi-country trials and overlapping with C&R's ASEAN expansion strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

C&R Research compliance and trust

Trust signal

Compliance1 record

C&R Research financial estimates

Financial estimate

Revenue estimate

Valuation estimate

C&R Research leadership team

Management profile

Number of profiles

Profiles4 records

C&R Research subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

C&R Research funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

C&R Research M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about C&R Research

What does C&R Research do?

C&R Research is Korea's first independent Contract Research Organization (CRO), founded in 1997, providing end-to-end clinical trial services for pharmaceutical, biotechnology, and medical device companies. Services span Phase 1-4 clinical trials, real-world studies, post-marketing surveillance, regulatory affairs, data management, biostatistics, pharmacovigilance, quality management, and medical device trials. The company has conducted 1,800+ trials with 500+ clinical experts and operates its proprietary imtrial clinical process automation platform.

Is C&R Research a public or private company?

C&R Research is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was C&R Research founded?

C&R Research was founded in 1997. It employs 51 to 100 people.

Where is C&R Research based?

C&R Research is headquartered in Yeoksamdong, South Korea, in the Asia region.

How does C&R Research make money?

Two revenue lines are on record. CRO Contract Research Services are the primary driver. The others are specialized Clinical Consulting.

Who are C&R Research's main competitors?

Broad incumbents on record are ICON plc, Fortrea (formerly LabCorp Drug Development / Covance), Parexel, IQVIA, Charles River Laboratories and WuXi AppTec. Direct peers are Medpace, Tigermed, LSK Global Pharma Services and Novotech.

Does C&R Research have an API?

Yes. imtrial is a clinical process automation platform that provides standard API access, enabling direct connection with clinical research platforms, pharmaceutical companies, hospitals, and CROs for workflow integration and data exchange.

What industry is C&R Research in?

C&R Research's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
KBRC&R Research lands US pivotal trial for Korea’s 1st insomnia DTxC&R Research has secured a contract to conduct a U.S. pivotal clinical trial for AIMneXt's digital therapeutic Somzz, Korea's first approved DTx for insomnia, as part of a government-supported program led by Seoul National University Hospital. C&R Research's medical device team will work alongside its U.S. subsidiary Trial Informatics to conduct the trials and support AIMneXt's FDA approval process using Trial Informatics' proprietary EDC platform. The project represents a reference case for Korean digital therapeutics companies seeking FDA approval and marks C&R Research's expansion beyond traditional drug-focused CRO services into the medical device and DTx sectors.FutureCIOTaimei Technology and C&R Research partner to build an AI-powered clinical trial innovationTaimei Technology, an AI-powered drug clinical development platform, and C&R Research, a South Korean Contract Research Organisation, have entered into a strategic partnership to develop AI-based clinical trial operations systems. The collaboration will integrate Taimei Technology's digital infrastructure and AI agents, including EDC and iDM systems, into C&R Research's existing clinical trial processes to automate data management, trial design, and operational workflows. The two companies aim to build a more efficient and intelligent clinical research framework tailored to Korea's CRO-centric clinical trial execution system.BusinessLineTaimei Technology and C&R Research Announce Strategic Partnership to Build AI-Powered Clinical Trial InnovationTaimei Technology and C&R Research signed a strategic partnership agreement to develop an AI-based clinical trial operations system, with C&R Research deploying Taimei Technology's digital infrastructure and AI Agents across multiple clinical trials. The partnership focuses on automating trial design and operational workflows, including data management with EDC + iDM Agent combinations and AI-driven eCRF generation to boost productivity in clinical research. The two companies plan to integrate AI-driven operational models with Korea's CRO-centric clinical trial execution system to accelerate the digital transformation of South Korea's clinical trial landscape.The HinduTaimei Technology and C&R Research Announce Strategic Partnership to Build AI-Powered Clinical Trial InnovationTaimei Technology and C&R Research signed a strategic partnership agreement to develop an AI-based clinical trial operations system, combining Taimei Technology's AI-powered digital infrastructure with C&R Research's CRO expertise in South Korea. The partnership will deploy Taimei Technology's AI Agent matrix, including the EDC + iDM Agent combination for intelligent data capture, governance, and automated workflows, aiming to enhance trial design and operational efficiency. Industry observers view this as a key catalyst for accelerating AI-driven digital transformation in South Korea's clinical trial landscape, where trial activity ranks among the top globally.The TribuneTaimei Technology and C&R Research Announce Strategic Partnership to Build AI-Powered Clinical Trial InnovationTaimei Technology and C&R Research signed an enterprise-level strategic partnership agreement on May 7, 2026, to jointly develop an AI-based clinical trial operations system for South Korea's clinical trial landscape. Under the partnership, C&R Research will deploy Taimei Technology's digital infrastructure and AI Agents, including the EDC + iDM Agent combination, across multiple clinical trials to automate trial design and operational workflows. The two companies aim to integrate AI-driven operational models with Korea's established CRO ecosystem to accelerate the digital transformation of clinical research in South Korea.PR NewswireTaimei Technology and C&R Research Announce Strategic Partnership to Build AI-Powered Clinical Trial InnovationTaimei Technology and C&R Research signed a strategic partnership agreement to develop AI-based clinical trial operations systems, with C&R deploying Taimei Technology's digital infrastructure and AI Agents across multiple clinical trials. The partnership will focus on data management using the EDC + iDM Agent combination, with innovations including intelligent data capture, AI-driven eCRF generation, and automated test case creation aimed at boosting productivity and quality in clinical research. The two companies plan to integrate AI-driven operational models with Korea's mature CRO-centric clinical trial ecosystem to build a more efficient and intelligent clinical research framework.PR Newswire APACTaimei Technology and C&R Research Announce Strategic Partnership to Build AI-Powered Clinical Trial InnovationTaimei Technology and C&R Research signed a strategic partnership to develop an AI-based clinical trial operations system. C&R will deploy Taimei's AI Agents across trials, focusing on data management and automation. The partnership aims to accelerate AI-driven digital transformation in South Korea's clinical trial landscape.The Manila TimesC&R Research, the 'K-Clinical Hub', Strengthens Partnerships in IndonesiaC&R Research, a South Korean contract research organization, is expanding its clinical trial capabilities in Indonesia as part of its global strategic growth. The company has focused on building local clinical understanding and strengthening regional collaborations, including a 2024 MOU with Korea's KIMCo in Thailand.YahooC&R Research, the 'K-Clinical Hub', Strengthens Partnerships in IndonesiaC&R Research, Korea's first full-service Contract Research Organization founded in 1997, is strengthening its clinical trial partnerships in Indonesia by leveraging its global network spanning Singapore, Thailand, and the United States. The company has built collaboration networks through chronic disease studies in Thailand and is focusing on type 2 diabetes as a key disease area in Indonesia. In 2024, C&R Research's Thailand subsidiary signed an MOU with the Korea Innovative Medicines Consortium (KIMCo) to strengthen Korea-Thailand clinical cooperation and expand regional frameworks supporting Korean pharmaceutical companies' entry into ASEAN markets.